Clinuvel Pharmaceuticals Ltd
ASX:CUV
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Clinuvel Pharmaceuticals Ltd
Common Stock
Clinuvel Pharmaceuticals Ltd
Common Stock Peer Comparison
Competitive Common Stock Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Common Stock
AU$169.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Immutep Ltd
ASX:IMM
|
Common Stock
AU$446.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
Mesoblast Ltd
ASX:MSB
|
Common Stock
$1.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Common Stock
$537m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Common Stock
AU$446.3m
|
CAGR 3-Years
39%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Common Stock
AU$157.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Common Stock?
Common Stock
169.6m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Common Stock amounts to 169.6m AUD.
What is Clinuvel Pharmaceuticals Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
3%
Over the last year, the Common Stock growth was 12%. The average annual Common Stock growth rates for Clinuvel Pharmaceuticals Ltd have been 4% over the past three years , 3% over the past five years , and 3% over the past ten years .